Details for Patent: 8,895,601
✉ Email this page to a colleague
Which drugs does patent 8,895,601 protect, and when does it expire?
Patent 8,895,601 protects BALVERSA and is included in one NDA.
This patent has seventy-five patent family members in thirty-eight countries.
Summary for Patent: 8,895,601
| Title: | Pyrazolyl quinoxaline kinase inhibitors |
| Abstract: | The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. ##STR00001## |
| Inventor(s): | Saxty; Gordon (Cambridge, GB), Murray; Christopher William (Cambridge, GB), Berdini; Valerio (Cambridge, GB), Besong; Gilbert Ebai (Bad Duerkheim, DE), Hamlett; Christopher Charles Frederick (Cambridge, GB), Johnson; Christopher Norbert (Cambridge, GB), Woodhead; Steven John (San Diego, CA), Rees; David Charles (Cambridge, GB), Mevellec; Laurence Anne (Louviers, FR), Angibaud; Patrick Rene (Fontaine-Bellenger, FR), Freyne; Eddy Jean Edgard (Rumst, BE), Perera; Timothy Pietro Suren (Geel, BE), Gilissen; Ronaldus Arnodus Hendrika Joseph (Kasterlee, BE), Wroblowski; Berthold (Vosselaar, BE), Lacrampe; Jean Fernand Armand (Le Mesnil-Esnard, FR), Papanikos; Alexandra (Antwerp, BE), Querolle; Oliver Alexis Georges (Evreux, FR), Pasquier; Elisabeth Therese Jeanne (Le Neubourg, FR), Pilatte; Isabelle Noelle Constance (Louviers, FR), Bonnet; Pascal Ghislain Andre (Berchem, BE), Embrechts; Werner Constant Johan (Beerse, BE), Akkari; Rhalid (Vacquieres, FR), Meerpoel; Lieven (Beerse, BE) |
| Assignee: | Astex Therapeutics Ltd (Cambridge, GB) |
| Application Number: | 13/643,741 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,895,601
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-002 | Apr 12, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,895,601
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 1007286.6 | Apr 30, 2010 |
| PCT Information | |||
| PCT Filed | April 28, 2011 | PCT Application Number: | PCT/GB2011/050851 |
| PCT Publication Date: | November 03, 2011 | PCT Publication Number: | WO2011/135376 |
International Family Members for US Patent 8,895,601
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 3210 | ⤷ Sign Up | |||
| Argentina | 080982 | ⤷ Sign Up | |||
| Australia | 2011247047 | ⤷ Sign Up | |||
| Australia | 2017202512 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
